Literature DB >> 11123027

The treatment of rheumatoid arthritis: a review of recent clinical trials.

T Mikuls1, L Moreland.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11123027     DOI: 10.1007/s11926-999-0010-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  40 in total

1.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Authors:  M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden
Journal:  Lancet       Date:  1997-08-02       Impact factor: 79.321

2.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

Authors:  L W Moreland; S W Baumgartner; M H Schiff; E A Tindall; R M Fleischmann; A L Weaver; R E Ettlinger; S Cohen; W J Koopman; K Mohler; M B Widmer; C M Blosch
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

3.  Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial.

Authors:  J R O'Dell; C E Haire; W Palmer; W Drymalski; S Wees; K Blakely; M Churchill; P J Eckhoff; A Weaver; D Doud; N Erikson; F Dietz; R Olson; P Maloley; L W Klassen; G F Moore
Journal:  Arthritis Rheum       Date:  1997-05

4.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Authors:  L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.

Authors:  D T Felson; J J Anderson; R F Meenan
Journal:  Arthritis Rheum       Date:  1992-10

6.  Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study.

Authors:  R Munro; R Hampson; A McEntegart; E A Thomson; R Madhok; H Capell
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

7.  Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Authors:  J S Smolen; J R Kalden; D L Scott; B Rozman; T K Kvien; A Larsen; I Loew-Friedrich; C Oed; R Rosenburg
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

8.  Effects of oral administration of type II collagen on rheumatoid arthritis.

Authors:  D E Trentham; R A Dynesius-Trentham; E J Orav; D Combitchi; C Lorenzo; K L Sewell; D A Hafler; H L Weiner
Journal:  Science       Date:  1993-09-24       Impact factor: 47.728

9.  Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone.

Authors:  T Pincus; S B Marcum; L F Callahan
Journal:  J Rheumatol       Date:  1992-12       Impact factor: 4.666

10.  Survival, prognosis, and causes of death in rheumatoid arthritis.

Authors:  D M Mitchell; P W Spitz; D Y Young; D A Bloch; D J McShane; J F Fries
Journal:  Arthritis Rheum       Date:  1986-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.